Loading clinical trials...
Loading clinical trials...
A Real-World Observational Study for the Safety and Efficacy of Baraclude (Entecavir) in Korean Pediatric (Aged 2-16 Years) Patients With Chronic Hepatitis B
This is a local, prospective observational study (regulatory post marketing surveillance) to access the safety and effectiveness of Baraclude in Korean pediatric patients with chronic HBV infection who are between the ages of 2 and less than 16 years.
Age
2 - 16 years
Sex
ALL
Healthy Volunteers
No
Local Institution
Seoul, South Korea
Start Date
January 12, 2018
Primary Completion Date
March 13, 2019
Completion Date
March 13, 2019
Last Updated
June 3, 2019
1
ACTUAL participants
Non-interventional
OTHER
Lead Sponsor
Bristol-Myers Squibb
NCT07024641
NCT06671093
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07275554